V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160013559 | 160006597 | 1.75 | 88 | Palliative (P) | 2017-12-24 | 2017-12-27 | Doxorubicin 75mg/m2 | 02 | N | CARBOPLATIN + PACLITAXEL | 101811609 |
| 160013560 | 160006598 | 1.61 | 80.5 | Palliative (P) | 2017-01-08 | 2017-01-08 | Doxorubicin + Ifosfamide | N | N | IVADO | 101867369 |
| 160013561 | 160006599 | 1.73 | 110 | Palliative (P) | 2014-06-17 | 2014-06-17 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101466545 |
| 160013562 | 160006600 | null | 99.4 | Adjuvant (A) | 2017-03-02 | 2017-03-16 | Etoposide oral | 02 | null | LIPOSOMAL DOXORUBICIN | 101707020 |
| 160013566 | 160006601 | 1.72 | 67.6 | Palliative (P) | 2017-09-02 | 2017-10-01 | VINCRISTINE | Y | N | TRIAL UNSPECIFIED | 101536081 |
| 160013567 | 160006602 | 1.62 | 53.8 | Palliative (P) | 2018-02-21 | 2018-02-23 | BEP 3 day | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101289929 |
| 160013570 | 160006603 | 1.61 | 100 | null | 2017-12-20 | 2017-12-27 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | null | N | TRIAL UNSPECIFIED | 101399376 |
| 160013572 | 160006604 | 0 | 0 | Curative (C) | null | 2019-05-17 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101195534 |
| 160013573 | 160006605 | 1.68 | 68.6 | Palliative (P) | 2018-07-29 | 2018-07-29 | Paclitaxel 80mg/m2 day 1 8 15 | 02 | N | VIDE | 100664893 |
| 160013574 | 160006606 | 1.55 | 75.8 | Palliative (P) | 2018-02-08 | 2018-02-16 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100896757 |
| 160013577 | 160006607 | null | 97 | Palliative (P) | 2020-01-11 | 2020-01-11 | DOCETAXEL + GEMCITABINE | 02 | null | ETOP 13-18 BEAT-MESO TRIAL | 100577065 |
| 160013579 | 160006608 | 1.61 | 55.2 | Curative (C) | 2017-04-19 | 2017-04-19 | GEMCARBO | 2 | N | VINCRISTINE | 101564724 |
| 160013581 | 160006609 | 1.78 | 83.9 | Curative (C) | 2018-06-18 | 2018-06-18 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101684169 |
| 160013582 | 160006610 | 1.8 | 18.25 | null | 2017-11-17 | 2017-11-17 | EW EuroEwing 2012 Arm A VAI | 02 | N | DOXORUBICIN + OLARATUMAB | 100163265 |
| 160013584 | 160006611 | 1.53 | 62.5 | Palliative (P) | 2017-09-14 | 2017-09-29 | STS Rhabdo RMS 2005 Vin Cyclo | null | N | DOXORUBICIN | 101509078 |
| 160013585 | 160006612 | null | 59 | Palliative (P) | 2018-07-30 | 2018-07-31 | Vinorelbine (oral) | 02 | N | ETOPOSIDE + IFOSFAMIDE | 100397738 |
| 160013591 | 160006613 | 1.78 | 58.6 | Palliative (P) | 2017-08-21 | 2017-08-21 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100491466 |
| 160013592 | 160006614 | 1.72 | 93.3 | Palliative (P) | 2019-10-08 | 2019-10-24 | STS Rhabdomyosarcoma RMS 2005 IVAVV | N | N | DOXORUBICIN + IFOSFAMIDE | 101039644 |
| 160013594 | 160006615 | 1.84 | 66.8 | Palliative (P) | 2017-07-14 | 2017-08-26 | CAP | N | null | STS RHABDO RMS 2005 | 100606212 |
| 160013599 | 160006616 | 0 | 41.6 | Palliative (P) | 2017-04-15 | 2017-04-16 | DABRAFENIB + TRAMETINIB | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101287367 |
| 160013600 | 160006617 | 1.6 | 54 | Palliative (P) | 2017-05-13 | 2017-05-20 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101626914 |
| 160013602 | 160006618 | 1.74 | 45 | null | 2017-12-14 | 2018-01-04 | Doxorubicin 75mg/m2 | 02 | null | DOXORUBICIN | 101744525 |
| 160013603 | 160006619 | null | 99 | Palliative (P) | 2016-02-26 | 2016-02-27 | CARBOPLATIN | 02 | null | CARBOPLATIN | 100351710 |
| 160013604 | 160006620 | null | 87.5 | Adjuvant (A) | 2018-11-11 | 2018-11-11 | DOXORUBICIN | 02 | N | DOXORUBICIN + OLARATUMAB | 101783386 |
| 160013605 | 160006621 | 1.66 | 84.9 | Palliative (P) | 2017-09-13 | 2017-10-08 | null | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101211297 |
| 160013606 | 160006622 | 1.64 | 92 | Palliative (P) | 2016-12-04 | 2016-12-05 | CHOP | 02 | N | DOXORUBICIN + OLARATUMAB | 100956525 |
| 160013607 | 160006623 | 1.76 | 95 | Palliative (P) | 2022-03-30 | 2022-03-31 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100190281 |
| 160013608 | 160006624 | 1.75 | 88 | Palliative (P) | null | 2016-07-06 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | VDC | 100087816 |
| 160013612 | 160006625 | 1.78 | 20 | Palliative (P) | null | 2019-07-17 | Doxorubicin + Olaratumab | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100317326 |
| 160013614 | 160006626 | 1.68 | 112 | Palliative (P) | 2017-01-17 | 2017-01-19 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100464150 |
| 160013616 | 160006627 | 1.69 | 83 | Palliative (P) | 2019-07-31 | 2019-09-22 | Cisplatin + Pemetrexed | 2 | N | CISPLATIN + PEMETREXED | 101318612 |
| 160013618 | 160006628 | 1.74 | 72.2 | Palliative (P) | 2016-07-25 | 2016-07-31 | Doxorubicin + Ifosfamide | 01 | N | PACLITAXEL | 100268367 |
| 160013619 | 160006629 | 1.7 | 79 | Palliative (P) | 2018-06-25 | 2018-07-08 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100742950 |
| 160013620 | 160006630 | 1.76 | 72.1 | Palliative (P) | 2016-06-14 | 2016-06-19 | EURO-EWING | 02 | N | LIPOSOMAL DOXORUBICIN | 100133707 |
| 160013621 | 160006631 | 1.7 | 67.6 | null | 2022-02-05 | 2022-02-05 | VIDE | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 101266315 |
| 160013622 | 160006632 | 1.65 | 68.2 | Neo-adjuvant (N) | 2016-04-14 | 2016-05-20 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | DOXORUBICIN | 101796037 |
| 160013623 | 160006633 | 1.62 | 74 | Neo-adjuvant (N) | 2017-10-14 | 2017-10-15 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 101637951 |
| 160013624 | 160006634 | 1.83 | 53.3 | Palliative (P) | 2017-08-31 | 2017-09-01 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | null | VDC | 101095478 |
| 160013625 | 160006635 | 1.76 | 68.6 | null | 2018-03-02 | 2018-03-08 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100115180 |
| 160013626 | 160006636 | 1.94 | 79.3 | Palliative (P) | 2019-12-08 | 2019-12-17 | Cisplatin + Pemetrexed | 2 | null | CISPLATIN + PEMETREXED | 100616264 |
| 160013627 | 160006637 | 1.79 | 61 | Palliative (P) | 2016-12-15 | 2016-12-16 | Cisplatin + Pemetrexed | 01 | N | CISPLATIN + PEMETREXED | 101791727 |
| 160013628 | 160006638 | 1.68 | 69 | Palliative (P) | 2016-09-30 | 2016-10-01 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 101570723 |
| 160013630 | 160006639 | 1.56 | 77 | Palliative (P) | 2018-01-02 | 2018-01-21 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100239657 |
| 160013631 | 160006640 | 1.63 | 68.7 | Palliative (P) | 2020-04-29 | 2020-05-12 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101740298 |
| 160013635 | 160006641 | 1.72 | 70.7 | Curative (C) | 2018-02-07 | 2018-02-22 | EW EuroEwing 2012 Arm A VIDE | Y | N | DOXORUBICIN + IFOSFAMIDE | 101157951 |
| 160013636 | 160006642 | null | null | Palliative (P) | null | 2012-10-09 | Doxorubicin + Ifosfamide | 02 | null | LIPOSOMAL DOXORUBICIN | 101104203 |
| 160013637 | 160006643 | 1.8 | 85.25 | Neo-adjuvant (N) | 2018-05-08 | 2018-05-22 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 100802611 |
| 160013643 | 160006644 | 1.95 | 8.18 | Palliative (P) | 2019-06-28 | 2019-06-28 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 100679484 |
| 160013644 | 160006645 | 1.74 | 88.3 | null | 2018-08-04 | 2018-09-07 | Vinorelbine (oral) | N | N | IPILIMUMAB + NIVOLUMAB | 101328747 |
| 160013646 | 160006646 | 1.67 | 65.5 | null | 2021-07-31 | 2021-07-31 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100539938 |